Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Quercis Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quercis Pharma Licenses Key Patents for Thromboembolism Platform Across Cancer and Covid-19 Indications","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"DeGregorio Family Foundation","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Grant Awarded to Develop Gastric Cancer Vaccine to Prevent Relapse After Surgery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Beth Israel Deaconess Medical Center

    Menu

    Beth Israel Deaconess Medical Center

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Beth Israel Deaconess Medical Center

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Grant Awarded to Develop Gastric Cancer Vaccine to Prevent Relapse After Surgery

              Details:

              The funding will be used for the development of a personalized dendritic cell/organoid-based vaccine for the treatment of patients with gastric cancer undergoing surgical resection.

              Lead Product(s): Dendritic Cell-based Vaccine

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: DeGregorio Family Foundation

              Deal Size: $0.5 million Upfront Cash: Undisclosed

              Deal Type: Funding February 01, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Beth Israel Deaconess Medical Center

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Quercis Pharma Licenses Key Patents for Thromboembolism Platform Across Cancer and Covid-19 Indications

              Details:

              The patents cover the inhibition of soluble P-selectin that helps to prevent and/or reduce thrombotic events. Quercis’ lead drug candidate ISQ950AN, acts as an antithrombotic with significantly lower risk of adverse events than existing therapies.

              Lead Product(s): Isoquercitrin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: ISQ950AN

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Quercis Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY